NRx Pharmaceuticals, Inc. Announces Pricing of $2.0 Million Underwritten Public Offering of Common Stock

1d ago, source:

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), ("NRx Pharmaceuticals" or the "Company"), a clinical-stage biopharmaceutical ...

NRx Pharmaceuticals, Inc. Announces Proposed Underwritten Public Offering of Common Stock

1d ago, source:

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)("NRx Pharmaceuticals" or the "Company"), a clinical-stage biopharmaceutical company, ...

NRx Pharmaceuticals Advances in Breakthrough Bipolar Depression Treatment

5d ago, source: MyChesCo on MSN

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) recently announced the completion of data collection in its pivotal Phase 2b/3 study ...

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Q4 2023 Earnings Call Transcript

17d ago, source: InvestingChannel on MSN

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Q4 2023 Earnings Call Transcript April 1, 2024 NRx Pharmaceuticals, Inc. isn't one of ...

NRx Pharmaceuticals: New Data Demonstrates No Impact Of NRX-101 On Gut Or Vaginal Flora

2d ago, source:

NRx Pharmaceuticals, Inc. (NRXP) reported new data that demonstrate that in a rodent model NRX-101 shows no measurable damage to ...

NRx Pharma develops new proprietary formulation of IV Ketamine for use as HTX-100

3d ago, source: Pharmabiz

NRx Pharma develops new proprietary formulation of IV Ketamine for use as HTX-100: Radnor, Pennsylvania Tuesday, April 16, 2024, 16:00 Hrs [IST] NRx Pharmaceuticals, Inc., a clini ...

NRX Pharmaceuticals Inc Ordinary Shares

24d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

NRx Pharmaceuticals (NASDAQ:NRXP) Announces Development of New, Proprietary Formulation of HTX-100 (IV Ketamine)

4d ago, source: Stockhouse

April 15, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", "NRx", the "Company"), a clinical-stage biopharmaceutical company, today announced that the Company has ...

NRx Pharmaceuticals (NASDAQ:NRXP) Reports Preliminary Fourth Quarter and Full Year 2023 Financial Results and Provides Year End Highlights

22d ago, source: WKRN-TV

Inc., and Lotus Pharmaceuticals, Inc. (1795.TW) under which the partners take over phase 3 and commercial costs for NRX-101 in bipolar depression and fund $330 million in commercial milestones ...

NRx Pharmaceuticals, Inc.: NRx Pharmaceuticals Announces Results of the Vote Held During the Special Meeting of Shareholders

29d ago, source: Finanznachrichten

Zeit Aktuelle Nachrichten 15:29 NRx Pharma Achieves Data-lock In Phase 2b/3 Suicidal Treatment Resistant Bipolar Depression Study 14:30 NRx Pharmaceuticals, Inc.: NRx Pharmaceuticals (NASDAQ:NRXP ...

NRx Pharmaceuticals, Inc.: NRx Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing

22d ago, source: Finanznachrichten

Common Stock Will Begin Trading on Split-Adjusted Basis on April 2, 2024 RADNOR, Pa., March 28, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company ...

NRX Pharmaceuticals, Inc. (NRXP) Q4 2023 Earnings Call Transcript

17d ago, source: Seeking Alpha

Good morning everyone and welcome to the NRx Pharmaceuticals, Inc. Fourth Quarter and Full Year 2023 Results Conference Call. [Operator Instructions] As a reminder, this conference call is being ...